Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, on which dates (a) new vaccination centres were established for and (b) existing vaccination centres were able to begin delivery of the Nuvaxovid covid-19 vaccine.

On 15 September 2022, the Joint Committee on Vaccination and Immunisation advised that in exceptional circumstances the Novavax COVID-19 vaccine, Nuvaxovid, may be used as a primary course and off-label as a booster vaccine when no clinically suitable United Kingdom-approved alternative is available. The deployment of Nuvaxovid began on 28 September 2022.

NHS England has requested that regional teams nominate sites. As this vaccine is available to those who have experienced allergic reactions to mRNA vaccines, the sites are based in complex case clinics which exist in hospitals where patients are referred routinely for allergies. There are currently 56 nominated sites in England with assurance for Nuvaxovid, which consists of 50 hospital hubs and six vaccination centres. A further five sites are currently undergoing assurance processes.